Epilepsy Research
Volume 50, Issue 1 , Pages 21-32 , June 2002

The clinical impact of new antiepileptic drugs after a decade of use in epilepsy

References 

  1. Annegers JF, Rocca WA, Hauser WA. Causes of epilepsy: contributions of the Rochester epidemiology project. Mayo Clin. Proc. 1996;71:570–605
  2. Annegers JF, Coan SP, Hauser WA, Leestma J, Duffell W, Tarver B. Epilepsy, vagal nerve stimulation by the NCP system, mortality, and sudden, unexpected, unexplained death. Epilepsia. 1998;39:206–212
  3. Appleton RE, Peters ACB, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment for infantile spasms. Epilepsia. 1999;40:1627–1633
  4. Arroyo S, de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Res. 2001;47:155–174
  5. Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41:1597–1607
  6. Beydoun, A., 2002. Antiepileptic drugs are efficacious in various pain states. In: Löscher, W., Schmidt, D. (Eds.), New Horizons in the development of antiepileptic drugs. Epilepsy Research.
  7. Boggs JG, Nowack WJ, Drinkard CR. Analysis of the ‘honey moon effect’ in adult epilepsy patients. Epilepsia. 2000;41(Suppl. 7):222
  8. Browne TR, Holmes GL. Epilepsy New Engl. J. Med. 2001;344:1145–1151
  9. Calabrese, J.R., 2002. The clinical impact of antiepileptic drugs in psychiatric disorders. In: Löscher, W, Schmidt, D. (Eds.), New Horizons in the development of antiepileptic drugs. Epilepsy Res.
  10. Cilio M, Kartashov AI, Vigavano F. The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res. 2000;47:1–7
  11. Dalby NO, Mody I. The process of epileptogenesis: a pathophysiological approach. Curr. Opin. Neurol. 2001;14:187–192
  12. Delanty N, French J. Treatment of Lennox–Gastaut Syndrome. Current recommendations. CNS Drugs. 1998;3:181–188
  13. Devinsky O. Patients with refractory seizures. New Engl. J. Med. 1999;340:1565–1570
  14. Dodson WE. Felbamate in the treatment of Lennox–Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia. 1993;34(Suppl. 7):S18–S24
  15. Dulac O, N'Guyen . The Lennox–Gastaut syndrome. Epilepsia. 1993;34(Suppl. 7):S7–S17
  16. Engel J. Surgical Treatment of the Epilepsies. second ed.. New York: Raven Press; 1993;
  17. Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia. 1998;39(5):495–501
  18. First Seizure Trial Group . Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic–clonic seizure. Neurology. 1993;43:478–483
  19. Fisher R, Vickrey BG, Gibson P, Hermann B, Penovich P, Scherer A, et al. The impact of epilepsy from the patient's perspective. I. Descriptions and subjective perceptions. Epilepsy Res. 2000;41:39–51
  20. Fisher R, Vickrey BG, Gibson P, Hermann B, Penovich P, Scherer A, et al. The impact of epilepsy from the patient's perspective. II. Views about thaerapy and health care. Epilepsy Res. 2000;41:53–61
  21. French J, Smith M, Faught E, Brown L. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 1999;52:1540–1545
  22. Hauser, A.A., Hesdorffer, D., 1990. Epilepsy: frequency, causes and consequences. Epilepsy Foundation of America.
  23. Hauser, W.A., 1992. The natural history of drug resistant epilepsy: epidemiological considerations. 5, 25–28.
  24. Hernandez TD. Preventing post-traumatic epilepsy after brain injury: weighing the costs and benefits of anticonvulsant prophylaxis. Trends Pharmacol. Sci. 1997;18:59–62
  25. Kalviäinen R, Nouvasianen I, Nikolskelainen E, et al.  Visual field defects assciated with initial vigabatrin monotherapy as compared with initial carbamazepine monotherapy. Epilepsia. 1998;39(Suppl. 2):5; abstract
  26. Kaufman D, Kelly J, Anderson T, Harmon D, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia. 1997;38:1265–1269
  27. Krakow K, Walker M, Otoul C, Sander JWAS. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology. 2001;56:1772–1774
  28. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New Engl. J. Med. 2000;342:314–319
  29. Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: a systematic review of efficacy. Pediatrics. 2000;105:E46
  30. Lhatoo SD, Wong ICK, Polizzi G, Sander JWAS. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia. 2000;41:1592–1596
  31. Löscher W. Animal models of intractable epilepsy. Prog. Neurobiol. 1997;53:239–258
  32. Löscher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation. Epilepsy Res. 1994;17:95–134
  33. Löscher, W., Schmidt, D., 2002. New horizons in the development of antiepieptic drugs. In: Löscher W, Schmidt, D. (Eds.), New Horizons in the Development of Antiepileptic Drugs. Epilepsy Research.
  34. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JWAS, Shorvon S. Factors predicting prognosis after presentation with seizures. Ann. Neurol. 2000;48:8333–8841
  35. Marson AG, Chadwick DW. New drug treatment for epilepsy. J. Neurol. Neurosurg. Psychiatry. 2001;70:143–147
  36. McNamara JO. Emerging insights into the genesis of epilepsy. Nature. 1999;399:A15–22
  37. Motte J, Trevathan E, Arvidsson JF, et al.  Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. Lamictal Lennox–Gastaut Study Group. New Engl. J. Med. 1997;337(25):1807–1812 Published erratum: 1998 New Engl. J. Med. 339 (12), 851–852
  38. Musicco, M., Behji, E., Solari, A., Viani, F., the First Seizure Trial Group, 1997. Treatment of frist tonic–clonic seizures does not improve the prognosis of epilepsy. 49, 991–998.
  39. O'Neil M, Perdun C, Wilson M, McGown S, Patel S. Felbamate-associated fatal hepatic necrosis. Neurology. 1996;46:1457–1459
  40. Ohtsuka Y, Amano R, Mizukawa M, Ohtahara S. Long-term prognosis of the Lennox–Gastaut syndrome. Jpn. J. Psychiatry Neurol. 1990;44(2):257–264
  41. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br. J. Clin. Pharmacol. 1996;42:531–543
  42. Perucca E, Beghi E, Dulac O, Shorvon S, Tomson T. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res. 2000;41:107–139
  43. Post, R.M., 2002. Are kindling-like mechanisms operative in epilepsy, pain states and psychiatric disorders? In: Löscher, W., Schmidt, D. (Eds.), New Horizons in the Development of Antiepileptic Drugs. Epilepsy Res.
  44. Quiske A, Helmstaedter C, Lux S, Elger CE. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res. 2000;39:121–125
  45. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res. 1999;34:109–122
  46. Rijckevorsel K, Boon P. The ‘number needed to treat’ with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs). Seizure. 2001;10:235–236
  47. Rzany B, Correia O, Kelly JP, et al.  Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case control study. Lancet. 1999;353:2190–2194
  48. Sachdeo R, Glauser T, Ritter F, Reife R, Lim P, Pledger G, et al. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Neurology. 1999;52:1882–1887
  49. Schmidt D. Diagnostic and therapeutic management of intractable epilepsy. In:  Schmidt D,  Morselli PL editor. Intractable Epilepsy. New York: Raven Press; 1986;p. 237–251
  50. Schmidt, D., 2001. Vagus Nerve stimulation for the treatment of epilepsy. Epilepsy and Behavior 2, S1–S65. In: Neurostimulation and Neuropsychiatric Disorders, a Special Supplement of Epilepsy and Behavior, D. Schmidt, et al. (Eds.), 2001.
  51. Schmidt D, Bourgeois B. A risk-benefit assessment of therapies for Lennox–Gqstaut syndrome. Drug Safety. 2000;22:467–477
  52. Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy. CNS Drugs. 1995;3:194–208
  53. Schmidt, D., Rogawski, M., 2002. New strategies for the development of antiepileptic drugs that prevent the development or progression of the epileptic progress. In: Löscher, W., Schmidt, D. (Eds.), New Horizons in the Development of Antiepileptic Drugs. Epilepsy Res.
  54. Schmidt D, Gram L, Brodie M, Krämer G, Perucca E, Kälviäinen , et al. Tiagabine in the treatment of epilepsy—a clinical review and a guide for the prescribing physician. Epilepsy Res. 2000;41:245–254
  55. Schmidt, D., Schachter, S.C. (Eds.), 2000. Epilepsy. Problem solving in clinical practice. M Dunitz, London, 1999.
  56. Schmidt D, Stefan H, Elger CE. Gabapentin-monotherapy in 503 patients with partial epilepsy dissatisfied with inital standard antiepileptic drug therapy. Nervenheilkunde. 2001;20:321–325 english abstract
  57. Silver JM, Shin C, McNamara JO. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy. Ann. Neurol. 1991;29:356–363
  58. Sutula TP, Hermann B. Progression in mesial temporal lobe epilepsy. Ann. Neurol. 1999;45:553–556
  59. Temkin NR, Jarell AD, Anderson GD. Antiepileptogenic agents: how close are we. Drugs. 2001;61:1045–1055
  60. The Felbamate Study Group in Lennox–Gastaut Syndrome . Efficacy of felbamate in childhood epileptic encephalopathy (Lennox–Gastaut syndrome). New Engl. J. Med. 1993;328(1):29–33
  61. Thompson C, Barthen M, Hopper D, Miller T, Quigg M, Hudspeth C, et al. Quantification of patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids. Epilepsia. 1999;40:769–776
  62. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. New Engl. J. Med. 2001;345:311–318
  63. Wong ICK, Chadwick DW, Fenwick PBC, Mawer GE, Sander JWAS. The long-term use of gabapentin, lamotigine, and vigabatrin in patients with chronic epilepsy. Epilepsia. 1999;40(10):1439–1445
  64. Zielinski JJ. Epileptics not in treatment. Epilepsia. 1974;15:203–210

PII: S0920-1211(02)00065-7

Epilepsy Research
Volume 50, Issue 1 , Pages 21-32 , June 2002

Article Tools

* Image Usage & Resolution